Philippe Chavatte - Search Results

Year	Number of Results
2002	3
2003	1
2004	3
2005	4
2006	5
2007	3
2008	4
2009	1
2010	3
2011	4
2012	4
2013	5
2014	6
2015	3
2016	4
2017	3
2018	4
2020	1
2021	1
2022	2

1

Therapeutical potential of CB₂ receptors in immune-related diseases.

Leleu-Chavain N, Desreumaux P, Chavatte P, Millet R. Leleu-Chavain N, et al. Among authors: chavatte p. Curr Mol Pharmacol. 2013 Nov;6(3):183-203. doi: 10.2174/1874467207666140219122337. Curr Mol Pharmacol. 2013. PMID: 24720538 Review.

2

Targeting peroxisome proliferator-activated receptors (PPARs): development of modulators.

Pirat C, Farce A, Lebègue N, Renault N, Furman C, Millet R, Yous S, Speca S, Berthelot P, Desreumaux P, Chavatte P. Pirat C, et al. Among authors: chavatte p. J Med Chem. 2012 May 10;55(9):4027-61. doi: 10.1021/jm101360s. Epub 2012 Feb 27. J Med Chem. 2012. PMID: 22260081 Review. No abstract available.

3

A computational view of COX-2 inhibition.

Chavatte P, Farce A. Chavatte P, et al. Anticancer Agents Med Chem. 2006 May;6(3):239-49. doi: 10.2174/187152006776930909. Anticancer Agents Med Chem. 2006. PMID: 16712452 Review.

4

GED-0507 attenuates lung fibrosis by counteracting myofibroblast transdifferentiation in vivo and in vitro.

Speca S, Dubuquoy C, Rousseaux C, Chavatte P, Desreumaux P, Spagnolo P. Speca S, et al. Among authors: chavatte p. PLoS One. 2021 Sep 16;16(9):e0257281. doi: 10.1371/journal.pone.0257281. eCollection 2021. PLoS One. 2021. PMID: 34529707 Free PMC article.

5

GED-0507 is a novel potential antifibrotic treatment option for pulmonary fibrosis.

Speca S, Dubuquoy C, Rousseaux C, Chavatte P, Desreumaux P, Spagnolo P. Speca S, et al. Among authors: chavatte p. Cell Mol Immunol. 2020 Dec;17(12):1272-1274. doi: 10.1038/s41423-020-0394-y. Epub 2020 Mar 12. Cell Mol Immunol. 2020. PMID: 32203183 Free PMC article. No abstract available.

6

Therapeutic Potential of Fatty Acid Amide Hydrolase, Monoacylglycerol Lipase, and N-Acylethanolamine Acid Amidase Inhibitors.

Tuo W, Leleu-Chavain N, Spencer J, Sansook S, Millet R, Chavatte P. Tuo W, et al. Among authors: chavatte p. J Med Chem. 2017 Jan 12;60(1):4-46. doi: 10.1021/acs.jmedchem.6b00538. Epub 2016 Nov 14. J Med Chem. 2017. PMID: 27766867 Review.

7

Switching invariant natural killer T (iNKT) cell response from anticancerous to anti-inflammatory effect: molecular bases.

Laurent X, Bertin B, Renault N, Farce A, Speca S, Milhomme O, Millet R, Desreumaux P, Hénon E, Chavatte P. Laurent X, et al. Among authors: chavatte p. J Med Chem. 2014 Jul 10;57(13):5489-508. doi: 10.1021/jm4010863. Epub 2014 Feb 12. J Med Chem. 2014. PMID: 24428717 Review.

8

Design, synthesis and biological evaluation of potent FAAH inhibitors.

Tuo W, Leleu-Chavain N, Barczyk A, Renault N, Lemaire L, Chavatte P, Millet R. Tuo W, et al. Among authors: chavatte p. Bioorg Med Chem Lett. 2016 Jun 1;26(11):2701-5. doi: 10.1016/j.bmcl.2016.04.004. Epub 2016 Apr 23. Bioorg Med Chem Lett. 2016. PMID: 27117424

9

Chlorinated and brominated bisphenol A derivatives: Synthesis, characterization and determination in water samples.

Doumas M, Rouillon S, Venisse N, Nadeau C, Pierre Eugene P, Farce A, Chavatte P, Dupuis A, Migeot V, Carato P. Doumas M, et al. Among authors: chavatte p. Chemosphere. 2018 Dec;213:434-442. doi: 10.1016/j.chemosphere.2018.09.061. Epub 2018 Sep 12. Chemosphere. 2018. PMID: 30243209

10

Development of novel oxazolo[5,4-d]pyrimidines as competitive CB₂ neutral antagonists based on scaffold hopping.

Tuo W, Bollier M, Leleu-Chavain N, Lemaire L, Barczyk A, Dezitter X, Klupsch F, Szczepanski F, Spencer J, Chavatte P, Millet R. Tuo W, et al. Among authors: chavatte p. Eur J Med Chem. 2018 Feb 25;146:68-78. doi: 10.1016/j.ejmech.2018.01.034. Epub 2018 Jan 16. Eur J Med Chem. 2018. PMID: 29360044

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results